financetom
Business
financetom
/
Business
/
Grab's deal to buy Singapore taxi firm might lessen competition, regulator says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Grab's deal to buy Singapore taxi firm might lessen competition, regulator says
Jul 11, 2024 2:47 AM

July 11 (Reuters) - Nasdaq-listed ride hailing company

Grab's deal to buy Singapore's private taxi firm

Trans-cab Holdings is likely to result in substantial lessening

of competition in the local market, the city-state's competition

watchdog said on Thursday.

Southeast Asian firm Grab had in July 2023 agreed to buy

Singapore's third-largest taxi operator without giving out a

specific deal value though local media had then speculated the

deal could be valued at around S$100 million ($74 million).

The Competition & Consumer Commission of Singapore said in a

statement on Thursday that ride-hail platforms which operate as

rivals to Grab would be deprived of drivers who work for

Trans-cab, in case the deal goes through.

The deal might thereby result in a "greater degree of

'stickiness' of Trans-cab drivers to Grab's ride-hail platform",

the regulator said, adding the proposed acquisition might

potentially reduce usage of Grab's rivals.

Grab and Trans-cab did not immediately respond to Reuters'

requests for comments.

($1 = 1.3473 Singapore dollars)

(Reporting by Shivangi Lahiri in Bengaluru; Editing by Mrigank

Dhaniwala)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Antibe Therapeutics Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
Antibe Therapeutics Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
Apr 1, 2024
08:26 AM EDT, 04/01/2024 (MT Newswires) -- Antibe Therapeutics Inc. ( ATBPF ) , which gained more than 4.5% last Thursday, on Monday announced that it received verbal notice from the U.S. Food and Drug Administration on March 28 that otenaproxesul has been placed on clinical hold, postponing the initiation of the planned Phase II trial. Antibe expects to receive...
Top Premarket Decliners
Top Premarket Decliners
Apr 1, 2024
08:19 AM EDT, 04/01/2024 (MT Newswires) -- Fractyl Health ( GUTS ) shares fell 19% Monday premarket after the company reported a wider Q4 net loss. CalciMedica ( CALC ) shares dropped 18% following a muted session. Vivos Therapeutics ( VVOS ) shares decreased by 17% after the company late Thursday reported lower annual revenue for the year ended Dec....
Sector Update: Consumer
Sector Update: Consumer
Apr 1, 2024
08:21 AM EDT, 04/01/2024 (MT Newswires) -- Consumer stocks were leaning higher pre-bell Monday with the Consumer Staples Select Sector SPDR Fund (XLP) recently inactive, while the Consumer Discretionary Select Sector SPDR Fund (XLY) was up 0.1%. Doma Holdings ( DOMA ) rose more than 35% after announcing its pending takeover by Title Resources Group for $6.29 per share in...
Nuvalent Insider Sold Shares Worth $1,654,311, According to a Recent SEC Filing
Nuvalent Insider Sold Shares Worth $1,654,311, According to a Recent SEC Filing
Apr 1, 2024
08:28 AM EDT, 04/01/2024 (MT Newswires) -- Deborah Ann Miller, Chief Legal Officer, on March 28, 2024, sold 22,000 shares in Nuvalent ( NUVL ) for $1,654,311. Following the Form 4 filing with the SEC, Miller has control over a total of 33,300 shares of the company, with 33,300 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1861560/000095017024038721/xslF345X03/ownership.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved